You are here

Investor Relations

Home

Message from our CEO

812x408 Jeffrey Leiden_0.png

Jeffrey Leiden, Chairman, President and CEO

Events & Presentations

Latest Press Releases

Date Title and Summary
Toggle Summary 48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS
48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS Research Triangle Park, NC, July 8, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) once-daily (QD) as part of a
Toggle Summary 59 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Study 107 After Not Achieving SVR with at Least One Prior Course of Treatment for Hepatitis C Virus Infection
<i>-56% of prior treatment null responder patients achieved SVR with a 48-week telaprevir-based regimen-</i> <br /> <i>-97% of prior treatment relapsers and 55% of prior treatment partial responders achieved SVR with 24-week or 48-week telaprevir-based regimens-</i> <br />
HCV
Toggle Summary 65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy in Phase 3 REALIZE Study
<i>-17% of people achieved SVR with pegylated-interferon and ribavirin alone in the control arm-</i> <br /> <i>-Safety and tolerability results were consistent with prior Phase 3 studies-</i> <br /> <i>-Completion of rolling New Drug Application submission on track for the fourth quarter 2010-</i> <br />
HCV

Copyright Nasdaq. Minimum 15 minutes delayed.